Ken Griffin V Tv Therapeutics Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.72 - $1.01 $17,727 - $24,868	-24,622 Reduced 50.39%	24,238 $19,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $1.02 $10,459 - $16,164	15,848 Added 48.01%	48,860 $32,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $1.37 $2,766 - $5,830	-4,256 Reduced 11.42%	33,012 $32,000
Q2 2022 Aug 15, 2022	BUY	$0.39 - $0.84 $14,534 - $31,305	37,268 New	37,268 $28,000
Q1 2022 May 16, 2022	SELL	$0.51 - $1.0 $48,001 - $94,120	-94,120 Closed	0 $0

Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.69 $33,450 - $59,506	-35,211 Reduced 27.23%	94,120 $94,000
Q3 2021 Nov 15, 2021	BUY	$1.53 - $2.22 $2,275 - $3,301	1,487 Added 1.16%	129,331 $198,000
Q2 2021 Aug 16, 2021	SELL	$2.27 - $3.44 $118,616 - $179,753	-52,254 Reduced 29.01%	127,844 $291,000
Q1 2021 May 17, 2021	BUY	$1.97 - $2.89 $354,793 - $520,483	180,098 New	180,098 $508,000
Q4 2020 Feb 16, 2021	SELL	$1.49 - $3.1 $21,631 - $45,005	-14,518 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.7 - $2.98 $6,631 - $11,624	3,901 Added 36.74%	14,518 $26,000
Q2 2018 Aug 10, 2018	BUY	$0.71 - $4.04 $7,538 - $42,892	10,617 New	10,617 $0

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.43B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.